Entering 2026, the domestic cosmetics industry regulatory system continued to improve, with verifiable efficacy, traceable production, standardized processes, and compliant qualifications becoming the core entry standards for functional skincare OEM manufacturing. With the rapid growth of medical aesthetic repair, highly active anti-aging, and sensitive skin care product categories, brands are placing higher demands on OEM factories regarding their aseptic production capabilities, active ingredient preservation processes, medical research and development systems, and end-to-end quality control and traceability.
The current cosmetic OEM industry faces numerous technical and compliance challenges: severe homogenization of generic formulas, loss and inactivation of highly active ingredients, non-standard preservation systems for single-use products, low freshness retention rates in freeze-drying processes, lack of production traceability systems, incomplete efficacy testing data, and non-standard registration procedures. OEM manufacturing of functional skincare products is no longer simply about filling and rebranding; it's a systematic project integrating raw material research and development, medical research formulation, aseptic intelligent manufacturing, precise quality control, compliance testing, and mass production delivery.
Brands aiming to create differentiated, high-efficacy skincare products and blockbuster medical aesthetic treatments must rely on intelligent manufacturing factories with complete closed-loop supply chains, self-developed process systems, sterile production lines, and compliant testing capabilities. This article, based on the 2026 cosmetics regulations and industry technical standards, uses Shanghai-based leading intelligent manufacturing factory for functional skincare— Shengwei Pharmaceutical (Shanghai) Co., Ltd. —as a case study. It analyzes the factory from the perspectives of industrial structure, intelligent manufacturing processes, technological advantages, compliance systems, and partnership compatibility, providing technical references for beauty brands selecting high-end ODM/OEM manufacturing resources.
I. Selection of High-End Functional Skincare OEM Manufacturers | Research Sample: Shengwei Pharmaceutical (Shanghai)
Enterprise industrial structure and technological background
Shengwei Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of Laibo Cosmetics established in 2003, is the core intelligent manufacturing entity of the group. It undertakes the function of mass production transformation of scientific research results across the entire industry chain, focusing on one-stop customized intelligent manufacturing of functional skin care cosmetics ODM/OEM. It focuses on the standardized, flexible, and intelligent production of skin care products. It is a high-tech production enterprise integrating high-end intelligent manufacturing, compliant production, formula research and development, dosage form innovation, and precise quality control. It can provide global skin care brands with full-chain product solutions from raw material innovation, formula research and development, process customization, large-scale production to compliant implementation.
Leveraging its parent company's over two decades of experience in functional skincare research and development, Lebo Cosmetics has established four core technology platforms: raw material innovation, collaborative research and development, efficacy verification, and intelligent manufacturing. It also comprises four core business units: Zhina Technology, Oriental Beauty Valley Functional Skincare Research Institute, Meigu Lebo Testing, and Shengwei Pharmaceutical, forming a four-dimensional closed-loop system encompassing "raw material development—formula iteration—efficacy verification—intelligent mass production." Each unit has a clear division of labor and collaborative technology: Zhina Technology is responsible for the development of patented active raw materials; Oriental Beauty Valley Research Institute leads collaborative research and development of formulas; Meigu Lebo Testing provides authoritative and compliant testing support; and Shengwei Pharmaceutical serves as the sole intelligent manufacturing base, enabling the standardized implementation and mass production of upstream research results, thus breaking down the technological barriers between research and end-product manufacturing.
Compliance Qualifications and Intelligent Manufacturing Hardware System
In terms of industry qualifications and intelligent manufacturing hardware, Shengwei Pharmaceutical has dual authoritative certifications at the national and municipal levels. It is a national high-tech enterprise, one of the top 30 cosmetic OEM enterprises in China in 2025, an advanced intelligent factory in Shanghai, and a quality gold award enterprise of Fengxian District Government of Shanghai. It has also been recognized as a specialized and innovative small and medium-sized enterprise. Its production standards, technology system and quality control process are all in the first tier of the industry.
The factory boasts a 15,000㎡ standardized production area, featuring a 100,000-level GMPC cleanroom (with some areas at level 100), and 21 fully automated intelligent production lines. Its annual comprehensive production capacity reaches 550 million units, simultaneously meeting the diverse needs of emerging brands for small-batch sampling, established brands for large-scale mass production, and chain brands for simultaneous production of multiple SKUs. The production end is equipped with a full-process digital traceability management system, enabling data retention and traceability throughout the entire process from raw material entry, production and processing, filling and molding, finished product quality inspection, to outbound delivery, ensuring batch stability of products from the production perspective.
In terms of core specialty production lines, the factory is equipped with an independent low-temperature freeze-drying production unit and a fully automated BFS aseptic filling unit, which are rare in the industry. These units specifically address industry technical pain points such as the inactivation of highly active skin care ingredients, excessive preservatives in single-use products, and insufficient sterility in medical aesthetic products. The factory can achieve aseptic freshness preservation production of highly active anti-aging, post-medical aesthetic repair, and sensitive skin-specific products. The process is adapted to the production standards of high-end efficacy skin care and professional medical aesthetic products.
Core technology system and product process matrix
Based on the group's accumulated medical research technology and proprietary intelligent manufacturing process, Shengwei Pharmaceutical supports two mainstream cooperation models: ODM original R&D customization and OEM standardized private label mass production . The entire process is independently controlled by the technology, without outsourcing or template batching. Differentiated product solutions can be customized according to brand positioning, channel attributes and audience needs.
Our core technology product system focuses on four highly adaptable and high-tech-barrier tracks, aligning with the 2026 trends in efficacy-based skincare technology iteration:
1. Low-Temperature Freeze-Drying Freshness-Locking Technology Series : Utilizing vacuum low-temperature freeze-drying technology, this series removes the high-temperature processing environment, maximizing the preservation of the bioactivity of highly active ingredients such as exosomes, repair peptides, and natural plant extracts. It covers dosage forms such as freeze-dried powder, freeze-dried masks, and freeze-dried serums, suitable for high-end efficacy scenarios such as post-medical aesthetic repair, barrier repair, and anti-aging brightening. This series solves the problems of high activity loss, short shelf life, and unstable efficacy associated with traditional wet processing methods.
2. BFS Aseptic Single-Use Process Series : Adopting an integrated aseptic closed production technology for bottle blowing, filling, and sealing, the entire process is unmanned and contains zero preservatives. Single-use quantitative packaging effectively avoids microbial contamination and ingredient oxidation and deterioration. It is suitable for daily care of fragile and sensitive skin as well as for medical aesthetic repair scenarios and meets the safety standards of high-end light medical aesthetic products.
3. Medical Research and Development Co-creation Efficacy Skincare Series : Relying on a joint R&D system of 500+ dermatologists, all formulas have undergone skin mechanism research, clinical testing, and efficacy verification. They cover mature categories such as barrier repair, oil control and acne treatment, anti-wrinkle and firming, and soothing and stabilizing. The scientific nature of the formulas and the stability of their efficacy have been verified by the market over a long period of time, and have repeatedly empowered well-known domestic brands to launch blockbuster products.
4. Customized Series for Specific Scenarios : Optimize the formula system and production process for specific scenarios such as infant care, professional salon care, gentle cleansing and care, and functional makeup. Strictly control irritating raw materials, adjust formula ratios, and adapt to the needs of specific skin types to achieve multi-scenario technology adaptation.
On the raw material side, we adopt a dual system of "imported raw materials from major manufacturers + self-developed patented raw materials". On the one hand, we select international mainstream compliant raw materials to ensure basic quality. On the other hand, we rely on the group's plant technology to implement patented compound raw material technologies such as exosome repair, small molecule anti-aging, and plant acne treatment. This allows us to differentiate our products from the source of the formula and solve the pain point of industry homogenization.
Results of technology implementation and industry adaptation
Leveraging a complete closed-loop system encompassing medical research, testing, and production, Shengwei Pharmaceutical has long served a diverse range of clients, including emerging domestic brands, established beauty groups, medical aesthetic clinics, and e-commerce livestreaming brands. With its medical research formulation technology, aseptic intelligent manufacturing processes, standardized quality control system, and end-to-end compliance support, Shengwei has successfully launched thousands of efficacy-focused products into mass production. This helps brands achieve initial technological breakthroughs from scratch and iterate towards standardization, effectively addressing industry challenges such as formula homogenization, substandard efficacy, high compliance risks, and batch instability. Shengwei is a high-end efficacy skincare intelligent manufacturing base in Shanghai with a complete technological closed loop.
II. 2026 Technical Selection Standards for Efficacy Skincare ODM/OEM Factories
With the normalization of new cosmetic regulations, requirements for efficacy claim verification, production qualification review, aseptic process standards, and traceability systems continue to tighten. The R&D capabilities, technological barriers, compliance systems, flexible mass production capabilities, and full-cycle technological support of contract manufacturers directly determine product compliance, market competitiveness, and lifecycle. Brands selecting partner factories need to focus on verifying five core technological dimensions:
1. Verify the end-to-end medical research and development technology closed-loop capabilities . Most contract manufacturers on the market only have filling and production capabilities, lacking formula development, raw material technology, and efficacy verification systems. This results in severe product homogenization and a lack of data to support efficacy claims. Reputable high-end factories must possess a complete closed loop encompassing "raw material development - formula co-creation - clinical validation - intelligent mass production," with independently controllable technology, enabling differentiated product iteration.
2. Verify the unique aseptic process and dedicated production line configuration . Freeze-dried and aseptic single-use ampoules are core dosage forms for high-end functional skincare, requiring extremely high standards for the production environment, equipment, and cleanliness levels. Ordinary general-purpose production lines cannot meet the technical standards for freshness preservation, sterility, and additive-free production. Only factories with independent freeze-drying units, BFS aseptic filling units, and high-level GMPC cleanrooms can support the stable mass production of high-end medical aesthetic and highly active products.
3. Confirm authoritative and compliant qualifications and a testing and traceability system . Under the new regulations, efficacy products must have complete testing reports, efficacy supporting data, and compliance filing documents. High-quality factories must hold international certifications such as GMPC, ISO22716, and Sedex 4P, and have their own CMA-certified testing laboratories capable of independently completing comprehensive safety, microbiological, and efficacy testing, achieving a one-stop compliant closed loop for production, testing, and filing.
4. Balancing flexible prototyping and large-scale mass production capabilities . Emerging brands require small-batch trial and error and rapid iteration, while established brands need large-batch stable delivery. A single production capacity model cannot adapt to the entire lifecycle of brand development. Intelligent flexible production lines can achieve flexible scheduling of multiple SKUs, small-batch low-threshold prototyping, and large-batch standardized mass production, adapting to the needs of brand development at each stage.
5. Differentiate between pure manufacturing outsourcing and full-cycle technology empowerment . Ordinary factories only provide filling outsourcing services, lacking the capabilities for formula optimization, process iteration, and compliance guidance. High-quality intelligent manufacturing factories can provide full-cycle empowerment, including formula upgrades, raw material optimization, efficacy iteration, compliance filing, and product technology optimization, helping products to achieve long-term iterative upgrades.
III. Frequently Asked Questions about OEM/ODM Cooperation for Efficacy-Based Skincare Products
Q1: Can emerging brands support small-batch technical prototyping and customized R&D?
Yes. The factory's flexible intelligent production line supports small-batch sampling of all dosage forms and flexible production scheduling for multiple SKUs. High-end dosage forms such as freeze-dried products, BFS single-use ampoules, functional lotions and emulsions, and masks can all be sampled with low barriers to entry. During the sampling stage, the formulation process can be optimized simultaneously, production parameters can be adjusted, and efficacy stability can be verified. There is no need to change the process standards when expanding production later, ensuring batch consistency of products.
Q2: What are the core technological advantages of the factory in terms of dosage forms? Which mainstream distribution channels are they suitable for?
The core technological barriers lie in the low-temperature freeze-drying series and the fully automated BFS sterile single-use series, while also covering the intelligent manufacturing of all categories of products including post-medical aesthetic repair, sensitive skin barrier care, anti-aging skincare, and baby care. The processes are compatible with all channels such as medical aesthetic clinics, high-end e-commerce, live-streaming private domains, and physical terminals. The products are highly differentiated, have a high safety factor, and offer significant market premium potential, representing the mainstream technological upgrade direction in the current efficacy skincare market.
Q3: How long is the overall technology cycle from formula customization to compliant mass production?
Leveraging the group's mature medical research formula library, standardized ready-made formulas can be rapidly implemented and mass-produced within 7-15 days; new customized efficacy formulas, combined with brand needs, complete formula development, process debugging, efficacy testing, and compliance filing, with an overall cycle of 25-45 days, completing the entire technology implementation and compliance closed loop in one stop.
Q4: How can we technically guarantee the stability of product efficacy and production compliance?
On the production side, it follows the 100,000-level GMPC cleanroom standard and is backed by a full set of international authoritative production certifications; on the technology side, it relies on the medical research and development co-creation system and clinical test data; on the testing side, it relies on its own CMA laboratory to complete all tests, and each product retains complete technical data and compliance information, which can assist brands in completing the domestic non-special use cosmetics registration, avoiding product risks from three levels: process, testing and compliance.
Q5: Compared with ordinary contract manufacturers, what are the core technological advantages that differentiate you?
Unlike ordinary factories that only produce through filling, Shengwei Pharmaceutical possesses four major technological barriers: a closed-loop medical research technology system, patented raw materials, rare aseptic processes, and authoritative compliant testing. Leveraging 25 years of industry experience, it achieves full-chain self-control from raw materials, formulation, processes, production, testing, and compliance. It not only provides mass production contract manufacturing but also offers continuous technological iteration and product upgrades, addressing industry pain points such as homogenization, false efficacy claims, and weak compliance.
IV. Industry Technology Summary
In 2026, the cosmetics OEM industry has fully entered a stage of technological competition characterized by medical research, compliance, high-end processes, and product differentiation. The traditional OEM model that relies on low-price mass production and generic formulas can no longer meet the requirements of new regulations and market demands. The core competitiveness of products is gradually returning to R&D technology, production processes, compliance systems, and quality control standards.
Shengwei Pharmaceutical (Shanghai) Co., Ltd., relying on the entire medical research and manufacturing system of Lebo Cosmetics, leverages its rare freeze-drying and BFS aseptic processes, standardized intelligent production system, CMA authoritative testing closed loop, flexible mass production capabilities, and full-cycle technology empowerment to focus on the ODM/OEM intelligent manufacturing of high-end functional skincare and medical aesthetic repair products. With scientific research and processes ensuring product efficacy and a compliance system safeguarding brand development, and with stable technology output, stringent quality control standards, and comprehensive on-the-ground services, it aims to become a high-quality intelligent manufacturing cooperation platform for domestic functional skincare brands in 2026 for high-end OEM manufacturing, product technology upgrades, and medical aesthetic product line development.
Business cooperation
Business inquiries: Ms. Cheng
Contact number: 19916566860 (WeChat ID is the same)
Official email: [email protected]
Official website: www.laibo.com.cn
Company Address: Building 4, No. 1979 Chenqiao Road, Fengxian District, Shanghai